Navigation Links
Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
Date:9/10/2008

im to build on this by testing short treatments of several doses in future trials," said Steve Harris, Circassia's CEO. "Our goal for ToleroMune is to provide a range of allergy therapies that effectively and quickly treat the underlying disease while also offering excellent safety. Consequently, these positive clinical results will not only contribute to the development of our cat allergy product, but will also provide the foundations for our other allergy programmes that utilize our ToleroMune technology."

In addition to their potential clinical benefits, Circassia's anti-allergy products would have significant market opportunities. Currently, over 150 million people suffer from allergic rhinitis in the US and Europe and the market for current treatments, despite their limitations, is approximately $12 billion per year. The prevalence of cat-dander allergy is high, with 1-in-6 Americans and nearly 10% of Europeans suffering from the condition. Existing treatments have a number of issues, either providing symptomatic relief only or requiring lengthy supervision by specialist physicians. In contrast, Circassia's ToleroMune technology has the potential to rapidly desensitize sufferers using extremely small sections of allergens (termed T-cell epitopes), which minimizes the potential for adverse reactions.

About Circassia

Circassia is a specialty biopharmaceutical company focused on developing medicines designed to control immune system responses. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. The company
'/>"/>

SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
2. Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose
3. TriMix Gel Achieves Success Among Men Who Have Failed to Achieve Erections With Viagra, Levitra and Cialis Type Tablets
4. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
5. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
6. CureDMs Diabetes Therapy Achieves Major Development Milestone
7. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
8. Bionomics Achieves US$1 Million Milestone Payment from Genmab
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
11. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... BEIJING , Aug. 3 /PRNewswire-Asia-FirstCall/ ... CCM ), operator of the largest,network of radiotherapy ... report its unaudited financial results for the second,quarter ended ... August 18, 2010 .,Concord Medical,s management will hold an ...
... BETHESDA, Md. , Aug. 2 /PRNewswire-Asia/ -- ... independent American provider of Western,healthcare products and services in the People,s ... quarter fiscal 2011,financial results on Monday, August 9, 2010 , before ... ET that day to discuss,financial results. , ...
Cached Medicine Technology:Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010 2Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010 3Chindex International to Report First Quarter 2011 Financial Results 2
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the American ... effort to further promote visibility and adoption of the top ... AMA journals available via its subscription services, EBSCO will now ... , Long known as both a subscription agency and ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... healing, but the numbers tell a different story. Too ... they,ve been admitted, and hospital-related infections continue to be ... , Now, a radical new high-tech software program developed ... is now catching on faster than the flu. ...
... to Include Solutions for Medical Equipment, Facility,Design, ... More, DALLAS and NEW YORK, Nov. ... with Siemens Corporation to provide a wide,range ... next generation of,physician-owned healthcare environments., (Logo: ...
... 3 Will Use Tobacco Settlement Money to Keep ... V. Corr, Executive Director, Campaign for,Tobacco-Free Kids, ... delivered a victory for the state,s kids and ... that will reduce smoking, save lives,and lower health ...
... of leukemia patient,s DNA may lead to routine gene ... -- In a genetics first, researchers report that ... person with acute myelogenous leukemia. , There were some ... already identified genetic alterations, were associated with the blood ...
... of Georgia announced today that it has received a ... Melinda Gates Foundation. The grant will support an ... A. Koni titled "Antibody-Dependent Cellular Cytotoxicity Targeted Against HIV-1 ... 104 grants recently announced by the Gates Foundation for ...
... LINTHICUM, Md., Nov. 5 Dialysis Corporation,of America ... has amended its secured,revolving credit facility with KeyBank ... financing. The three-year agreement provides for both,base rate ... based, respectively,upon either the bank,s base rate or ...
Cached Medicine News:Health News:Reducing epic proportions 2Health News:Cirrus Health and Siemens Announce Technology Alliance to Deliver the Physician-Driven Hospital of the Future 2Health News:Cirrus Health and Siemens Announce Technology Alliance to Deliver the Physician-Driven Hospital of the Future 3Health News:North Dakota Votes to Keep Promise to Kids by Fully Funding Tobacco Prevention 2Health News:First-Ever Mapping of Cancer Patient's Genome 2Health News:First-Ever Mapping of Cancer Patient's Genome 3Health News:MCG receives $100,000 Grand Challenges Explorations grant for innovative global health research 2Health News:Dialysis Corporation of America Announces $25 Million Credit Facility 2
... The STA Compact CT is ... analyzer capable of performing clotting ... The system's unique method of ... and rapid processing of STAT ...
... synthesized in the parafollicular C-cells of the ... granules. The major action of calcitonin is ... osteoclast activity, resulting in decreased mobilization of ... most evident in conditions associated with high ...
... 68 kDa protein, which is produced primarily during ... sac [1]. Human fetal serum AFP levels ... reach 19-26 g/min during mid-gestation (14-20 weeks). ... AFP continue to increase after mid-gestation, a gradual ...
... (hCG) is a two chain (alpha- and ... tissue of the placenta and is normally ... Produced by the trophoblastic epithelium of the ... luteum in the early stages of pregnancy. ...
Medicine Products: